Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution

Journal of Clinical Microbiology

Volumn 49, Issue 2, 2011, Pages 630-637

  Pfaller, M A ^a   Boyken, L ^a   Hollis, R J ^a   Kroeger, J ^a   Messer, S A ^a   Tendolkar, S ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; KLUYVEROMYCES MARXIANUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; WILD TYPE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; TRIAZOLES;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 79951499139     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02161-10     Document Type: Article

References (53)

1. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
2. Ally, R., et al. 2001. A randomized, double-blind, double-dummy, multi-center trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin. Infect. Dis. 33:1447-1454.
3. Arendrup, M. C., and D. W. Denning. 2007. Does one voriconazole break-point suit all Candida species? J. Clin. Microbiol. 45:2093-2094.
4. Arendrup, M. C., G. Kahlmeter, J. L. Rodriguez-Tudela, and J. P. Donnelly. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53:1628-1629.
5. Armstrong-James, D. 2007. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J. Antimicrob. Chemother. 60:459-460.
6. Arnold, H. M., et al. 2010. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 30:361-368.
7. Chandrasekar, P. H., and E. Manavathu. 2001. Voriconazole: a second generation triazole. Drugs Today 37:135-148.
8. Chryssanthou, E., and M. Cuenca-Estrella. 2002. Comparison of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing proposed standard and the E-test with the NCCLS broth microdilution method for voriconazole and caspofungin susceptibility testing of yeast species. J. Clin. Microbiol. 40:3841-3844.
9. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
10. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
11. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
12. Corona, A., F. Cislaghi, and M. Singer. 2008. Timely selection of adequate antifungal therapy for candidemia in the critically ill: don't let the yeast rise! Crit. Care Med. 36:3097-3098.
13. Diekema, D. J., et al. 2007. Evaluation of Etest and disk diffusion methods compared with broth microdilution antifungal susceptibility testing of clinical isolates of Candida spp. against posaconazole. J. Clin. Microbiol. 45:1974-1977. (Pubitemid 46933937)
14. Espinel-Ingroff, A., et al. 2005. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole. J. Clin. Microbiol. 43:3884-3889.
15. Espinel-Ingroff, A., et al. 2005. Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study. J. Clin. Microbiol. 43:4535-4540. (Pubitemid 41298239)
16. Espinel-Ingroff, A., E. Canton, J. Peman, M. G. Rinaldi, and A. W. Fothergill. 2009. Comparison of 24-hour and 48-hour voriconazole MICs as determined by the Clinical and Laboratory Standards Institute broth microdilution method (M27-A3 document) in three laboratories: results obtained with 2,162 clinical isolates of Candida spp. and other yeasts. J. Clin. Microbiol. 47:2766-2771.
17. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 2008. EUCAST technical note on fluconazole. Clin. Microbiol. Infect. 14:193-195.
18. European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST). 2008. EUCAST technical note on voriconazole. Clin. Microbiol. Infect. 14:985-987.
19. Garey, K. W., et al. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
20. Garey, K. W., R. S. Turpin, D. T. Bearden, M. P. Pai, and K. J. Suda. 2007. Economic analysis of inadequate fluconazole therapy in non-neutropenic patients with candidemia: a multi-institutional study. Int. J. Antimicrob. Agents 29:557-562.
21. Hazen, K. C., and S. A. Howell. 2007. Candida, Cryptococcus, and other yeasts of medical importance, p. 1762-1788. In P. R. Murray, E. J. Baron, J. H. Jorgenson, M. L. Landry, and M. A. Pfaller (ed.), Manual of clinical microbiology, 9th ed. ASM Press, Washington, DC.
22. Herbrecht, R., et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
23. Hsu, D. I., M. Nguyen, L. Nguyen, A. Law, and A. Wong-Beringer. 2010. A multicenter study to evaluate the impact of timing of caspofungin administration on outcomes of invasive candidiasis in non-immunocompromised adult patients. J. Antimicrob. Chemother. 65:1765-1770.
24. Kahlmeter, G., et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148.
25. Kahlmeter, G., and D. F. J. Brown. 2004. Harmonization of antimicrobial breakpoints in Europe - can it be achieved? Clin. Microbiol. Newsl. 26:187-192.
26. Kullberg, B. J., et al. 2005. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet 366:1435-1442. (Pubitemid 41483809)
27. Labelle, A. J., S. T. Micek, N. Roubinian, and M. H. Kollef. 2008. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit. Care Med. 36:2967-2972.
28. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
29. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying empiric treatment of Candida blood-stream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645.
30. Nagappan, V., and S. Deresinski. 2007. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect. Dis. 45:1610-1617.
31. Ostrosky-Zeichner, L., et al. 2008. Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. Antimicrob. Agents Chemother. 52:4175-4177.
32. Panackal, A. A., et al. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743. (Pubitemid 43726263)
33. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618.
34. Perfect, J. R., et al. 2003. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 36:1122-1131.
35. Pfaller, M. A., et al. 2006. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
36. Pfaller, M. A., et al. 2008. Validation of 24-hour fluconazole MIC readings versus the CLSI 48-hour broth microdilution reference method: results from a global Candida antifungal surveillance program. J. Clin. Microbiol. 46:3585-3590.
37. Pfaller, M. A., et al. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559.
38. Pfaller, M. A., and D. J. Diekema. 2010. Wild-type MIC distributions and epidemiologic cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Rep. 4:168-174.
39. Pfaller, M. A., et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
40. Raad, I. I., et al. 2006. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis. 42:1398-1403.
41. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
42. Rodriguez-Tudela, J. L., et al. 2008. EUCAST definitive document EDef 7.1: method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts. Clin. Microbiol. Infect. 14:398-405.
43. Simjee, S., P. Silley, H. O. Werding, and R. Bywater. 2008. Potential confusion regarding the term "resistance" in epidemiological surveys. J. Antimicrob. Chemother. 61:228-229.
44. Skiest, D. J., et al. 2007. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis. 44:607-614.
45. Stevens, D. A., et al. 2007. Posaconazole therapy for chronic refractory coccidioidomycosis. Chest 132:952-958.
46. Turnidge, J., G. Kahlmeter, and G. Kronvall. 2006. Statistical characterization of bacterial wild-type MIC value distributions and determination of epidemiological cutoff values. Clin. Microbiol. Infect. 12:418-425.
47. Turnidge, J., and D. L. Paterson. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408.
48. Ullmann, A. J., et al. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666.
49. Vazquez, J. A., et al. 2006. A mulitcenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis. 42:1179-1186.
50. Vazquez, J. A., et al. 2007. Safety and efficacy of posaconazole in the longterm treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin. Trials 8:86-97. (Pubitemid 46953299)
51. Walsh, T. J., et al. 2002. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr. Infect. Dis. J. 21:240-248.
52. Walsh, T. J., et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12.
53. Zilberberg, M. D., et al. 2010. Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect. Dis. 10:150-156.